First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and serious
CymaBay Therapeutics Inc (NASDAQ: CBAY) shares are trading higher by 9.30% to $7.22 Tuesday morning. The company priced a public offering of common stock and pre-funded warrants at $7 per share and $6.999 per warrant.
What Else?